382 related articles for article (PubMed ID: 30909967)
1. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
3. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.
Hong BY; Ford JR; Glitza IC; Torres Cabala CA; Tetzlaff M; Prieto VG; Parker R; Daniel C; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2021 Jan-Feb 01; 37(1):e9-e13. PubMed ID: 32618825
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection.
Kikuchi I; Kase S; Ishijima K; Ishida S
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2271-2276. PubMed ID: 28752368
[TBL] [Abstract][Full Text] [Related]
6. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
7. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
10. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
11. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM
Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722
[TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
13. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
14. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.
Demirci H; McCormick SA; Finger PT
Arch Ophthalmol; 2000 Jul; 118(7):885-91. PubMed ID: 10900099
[TBL] [Abstract][Full Text] [Related]
15. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
Zhao CY; Hwang SJE; Wakade D; Carlos G; Anforth R; Fernández-Peñas P
Australas J Dermatol; 2017 Nov; 58(4):292-298. PubMed ID: 28707403
[TBL] [Abstract][Full Text] [Related]
16. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU
Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
Bastiaannet E; Battisti N; Loh KP; de Glas N; Soto-Perez-de-Celis E; Baldini C; Kapiteijn E; Lichtman S
J Geriatr Oncol; 2019 May; 10(3):389-397. PubMed ID: 30025821
[TBL] [Abstract][Full Text] [Related]
18. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
Valnet-Rabier MB; Marcucci C; Limat S; Davani S; Aubin F; Nerich V
Therapie; 2019 Jun; 74(3):355-367. PubMed ID: 30193804
[TBL] [Abstract][Full Text] [Related]
19. Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy.
Chang M; Lally SE; Dalvin LA; Orloff MM; Shields CL
Indian J Ophthalmol; 2019 Dec; 67(12):2071-2073. PubMed ID: 31755463
[TBL] [Abstract][Full Text] [Related]
20. Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.
Sa HS; Daniel C; Esmaeli B
J Ophthalmic Vis Res; 2022; 17(3):405-412. PubMed ID: 36160103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
